Drug Trial Radar · NCT00054587
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,010
Actual
Start
Jun 2001
Primary completion
Jun 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 6, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of chemotherapy plus radiation therapy with or without trastuzumab is more effective in treating breast cancer. PURPOSE: Randomized phase III trial to compare two different chemotherapy regimens plus radiation therapy with or without trastuzumab in treating women who have breast cancer that has spread to lymph nodes in the axilla (under the arm).
Conditions
- Breast Cancer
Interventions
TrastuzumabBiological
8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
CyclophosphamideDrug
500 mg/m², D1 and every 3 weeks
docetaxelDrug
on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
EpirubicinDrug
100 mg/m², D1 and every 3 weeks
FluorouracilDrug
500 mg/m², D1 and every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 5 years from randomization
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Centre Paul Papin
Angers, France
Centre Hospitalier d'Annecy
Annecy, France
Institut Bergonie
Bordeaux, France
C.H. Bourg En Bresse
Bourg-en-Bresse, France
Centre Regional Francois Baclesse
Caen, France
Centre Jean Perrin
Clermont-Ferrand, France
Hopital Intercommunal De Creteil
Créteil, France
Centre de Lutte Contre le Cancer Georges-Francois Leclerc
Dijon, France
Institut Prive de Cancerologie
Grenoble, France
Clinique du Petit Colmouilins
Harfleur, France
Centre Hospitalier de Lagny
Lagny-sur-Marne, France
Hopital Andre Mignot
Le Chesnay, France
CMC Les Ormeaux
Le Havre, France
Institut J. Paoli and I. Calmettes
Marseille, France
Centre Hospitalier Regional Metz Thionville
Metz, France
Centre Hospitalier General Andre Boulloche
Montbéliard, France
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France
Centre Hospitalier de Mulhouse
Mulhouse, France
Centre Regional Rene Gauducheau
Nantes-Saint Herblain, France
Hopital Avicenne
Paris, France
Clinique Saint - Pierre
Perpignan, France
CHU Poitiers
Poitiers, France
Institut Jean Godinot
Reims, France
Centre Eugene Marquis
Rennes, France
Clinique Sainte Clotilde
Sainte Clotilde, France
Centre Paul Strauss
Strasbourg, France
Hopitaux Universitaire de Strasbourg
Strasbourg, France
Institut Claudius Regaud
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.